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Background & aims: We aimed to develop and evaluate a pathway for 
management of patients with non-alcoholic fatty liver disease (NAFLD) using 
blood tests to stratify patients in primary care to improve detection of cases of 
advanced fibrosis and cirrhosis, and avoid unnecessary referrals to secondary 
care. 
Methods: This was a prospective longitudinal cohort study with before-and-
after analysis and comparison to unexposed controls. We used a two-step 
algorithm combining the use of FIB-4 followed by the ELF test if required. 
Results: In total, 3,012 patients were analysed. Use of the pathway detected 
5 times more cases of advanced fibrosis (Kleiner F3) and cirrhosis (OR=5.18; 
95%CI=2.97 to 9.04; p<0.0001). Unnecessary referrals from primary care to 
secondary care fell by 81% (OR=0.193; 95%CI 0.111 to 0.337; p<0.0001). 
Three times more cases of cirrhosis were diagnosed (OR=3.14; 95%CI=1.57 
to 24; p=0.00011). Although it was used for only 48% of referrals, significant 
benefits were observed across all referrals from the practices exposed to the 
pathway. Unnecessary referrals fell by 77% (OR=0.23; 95% CI=0.658 to 
0.082; p=0.006) with a 4-fold improvement in detection of cases of advanced 
fibrosis and cirrhosis (OR=4.32; 95% CI=1.52 to 12.25; p=0.006).  Compared 
to referrals made before introduction of the pathway, unnecessary referrals 
fell from 79/83 referrals (95.2%) to 107/152 (70.4%) representing an 88% 
reduction in unnecessary referrals when the pathway was followed  
(OR=0.12; 95%CI=0.042 to 0.349; p<0.0001). 
Conclusions: The use of non-invasive blood tests for liver fibrosis to stratify 
patients with NAFLD improves the detection of cases of advanced fibrosis and 
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cirrhosis and reduces unnecessary referrals to secondary care of patients with 
lesser degrees of liver fibrosis. This strategy improves resource use and 
benefits patients. 
Lay summary:  Non-alcoholic fatty liver disease effects up to 30% of the 
population but only a minority of cases develop liver disease. Our study has 
shown that established blood tests can be used in primary care to stratify 
patients with fatty liver disease to reduce unnecessary referrals by 80% and 
improve the detection of cases of advanced fibrosis 5 fold and cirrhosis 3 fold.
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Non-alcoholic fatty liver disease (NAFLD) is the commonest cause of 
deranged liver blood tests (LFTs) in primary care in Europe and North 
America [1], and has an estimated prevalence of 25-30% in the adult 
population[2]. Only a minority of people with NAFLD (5%) develop clinically 
significant liver disease [2], but the burden is such that NAFLD is predicted to 
be the leading indication for liver transplantation within a decade[3]. 
The majority of patients with NAFLD are followed up in the community by 
general practitioners (GPs). Liver fibrosis severity is the key determinant of 
liver-related outcomes in NAFLD [4-6]. However, identifying patients with 
significant fibrosis who might benefit from early specialist intervention is 
challenging. As clinical assessment is a poor discriminator of fibrosis, such 
patients progress silently until cirrhosis leads to complications. Accurate 
fibrosis assessment in primary care is limited by a reliance on LFTs, which 
correlate poorly with fibrosis [7, 8] and limited access to discriminatory fibrosis 
tests. Thus current management strategies are inefficient in identifying 
patients for specialist referral. Patients with mild disease are often referred for 
specialist review when the appropriate preventative interventions of lifestyle 
changes can be delivered effectively in primary care [9, 10]. Conversely, 
patients with advanced fibrosis or cirrhosis who will benefit from specialist 
interventions including clinical trials and cirrhosis surveillance often remain 
undetected until they present with cirrhosis complications including 
hepatocellular carcinoma. This ineffective management contributes to the 
poor outcomes associated with liver disease and the increasing trends in 
NAFLD-related morbidity and mortality. 
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The evolution of non-invasive liver fibrosis tests has created the opportunity 
for GPs to use these tests in innovative pathways that permit earlier 
identification of patients with chronic liver disease and subsequent access to 
specialist care [11]. An example of this approach is outlined in the recent 
British Society for Gastroenterology guidance on the management of 
abnormal LFTs that recommends the use of non-invasive tests to stratify 
patients at risk of CLD [12].
Whilst there is little evidence supporting the application of non-invasive tests 
in community settings, with only one study focusing on patients with NAFLD 
[13], guidelines recommend a two-tier approach to detect the presence of 
advanced fibrosis in NAFLD using either FIB-4 or NAFLD Fibrosis score, as 
an inexpensive first screen, in a combined cut-off approach with indeterminate 
scores retested using more sensitive and specific tests, ELF™ or FibroScan®, 
that are more costly[14]. 
Through broad consultation, a care pathway for patients identified with 
NAFLD in primary care was developed using non-invasive fibrosis 
assessment (FIB-4 followed by ELF™) to stratify patients to either remain in 
primary care or to be referred to secondary care. We present a prospective 




Materials and Methods 
Study setting and Design
The Camden and Islington NAFLD Pathway (hereafter the “NAFLD pathway”) 
was developed as a service innovation in conjunction with the primary care 
Clinical Commissioning Groups (CCG) of the London boroughs of Camden 
and Islington (C&I), between April 2013 and March 2014 and then introduced 
into practice. The NAFLD pathway working group met regularly to develop a 
pathway for the management of patients with NAFLD aiming to identify 
patients with advanced liver fibrosis (≥Kleiner F3), who might benefit from 
referral to secondary care for specialist hepatology review while identifying 
and managing patients with lesser degrees of fibrosis in primary care. The 
composition and aims of the working group including patient and public 
involvement are described in the Appendix. The pathway evaluation was 
conducted between March 2014 and May 2016 with the aim of determining 
the impact of the pathway in reducing unnecessary referrals and increasing 
the detection and referral of patients with advanced fibrosis. The pathway was 
introduced into C&I CCGs representing two of the 25 CCGs making referrals 
to the liver specialist services at The Royal Free London NHS Foundation 
Trust, The Whittington Hospital NHS Trust and University College London 
Hospitals NHS Foundation Trust, accounting for 43% of the referrals in 2012-
13. All practices within the two CCGs adopted the pathway but individual GPs 
within C&I were at liberty to follow it or to use Standard Care for each referral. 
The evaluation was conducted as a longitudinal study in which C&I 
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represented the CCGs exposed to the pathway and the remaining 23 CCGs 
represented the control CCGs. 
The Camden and Islington NAFLD Pathway 
All subjects aged 18 and over attending their GP with a new or established 
diagnosis of NAFLD were eligible for entry. For the pathway purposes, 
NAFLD was diagnosed in patients with steatosis on ultrasound, negative 
screens for other causes of liver disease and no alcohol excess (defined as 
>21 units of alcohol/week in males, >14 units/week in females). 
The pathway consisted of a two-step non-invasive test assessment, starting 
with the calculation of the FIB-4 score (Figure 1). Patients with FIB-4<1.30 
were deemed to be at low risk of advanced fibrosis (<F3) and remained in 
primary care [15]. Primary care management consisted of treatment of 
cardiovascular risks and diabetes, annual LFTs, and re-assessment of the risk 
of advanced fibrosis after 3-5 years. Patients with FIB-4>3.25 were deemed to 
be at high risk of advanced fibrosis and were recommended for referral to 
secondary care for specialist assessment. Patients with indeterminate FIB-4 
values (≥1.30 and <3.25) had second tier testing with an ELF™ test. Patients 
with ELF™ scores <9.5 were recommended to remain in primary care while 
those with an ELF™ score ≥9.5 were recommended for referral to secondary 
care [16, 17]. 
Evaluation of Standard Care 2012-2013 prior to pathway introduction:
A retrospective audit of referrals to secondary care by GPs was undertaken 
between 01/03/2012 and 28//02/2013 to determine the referrers’ ability to 
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identify patients with advanced fibrosis using Standard Care. The case 
records of all patients assigned a Read Code and referred with a diagnosis of 
NAFLD were reviewed by hepatologists in the receiving hospital and 
evaluated for evidence of advanced fibrosis/cirrhosis (≥F3) based on a 
composite of history, physical examination, blood tests, imaging, FibroScan®, 
and liver histology when available. FIB-4 scores were calculated and patients 
with FIB-4<1.30 were deemed to have no evidence of liver fibrosis and thus 
referred inappropriately. Referrals originating from primary care practices 
within the C&I CCGs were analysed separately from those referred from other 
CCGs.
Pathway evaluation:
Following introduction of the NAFLD pathway, data were collected on the 
outcomes of NAFLD referrals for patients seen at the secondary care sites. 
The CCG of the referral origin and use of the NAFLD pathway or Standard 
Care were recorded. The primary care electronic patient record systems 
(EMISWeb, Egton Medical Information Systems) were interrogated centrally 
to obtain data on NAFLD diagnosis and use of the pathway to stratify patients 
for referral using READ codes in primary care. Secondary care electronic 
medical records were interrogated to extract data related to patient 
demographics, secondary care management, fibrosis staging and clinical 
events. 
The diagnostic performance of the NAFLD pathway in detecting cases of 
advanced fibrosis was assessed against a reference standard composite 
clinical evaluation performed by expert hepatologists blind to the use of the 
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NAFLD pathway, as described above. All decisions were reviewed by the 
study team (AS and WMR) and any differences of opinion between the 
experts and the study team (<10% of cases) were resolved through 
discussion. 
Secondary care evaluation of the patients consisted of more analyses 
and in most cases a Fibroscan independently of the use of the pathway.  
A subset of 35/152 referrals from C&I deemed to have advanced fibrosis 
underwent liver biopsy following clinical assessment. Biopsies were staged for 
fibrosis by a single histopathologist who was blinded to use of the pathway 
(Supplementary Table 1). 
The distribution of FIB-4 scores in patients assessed by C&I GPs before and 
after introduction of the pathway was compared to look for evidence of bias in 
patient selection.
Outcomes 
The primary outcome was the reduction in the proportion of patients with 
NAFLD referred to secondary care who did not have evidence of advanced 
fibrosis based on clinical evaluation and were thus deemed to have been 
referred unnecessarily.
Secondary outcomes included:
 The number of cases and proportion of those referred who were 
deemed to have advanced fibrosis or cirrhosis after assessment by a 
liver specialist (true positive rate).
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 Proportion of patients diagnosed with NAFLD avoiding referral after 
primary care stratification. 
 Number of patients coded for NAFLD by GP before and after 
introduction of the pathway.
Sensitivity analyses were conducted to determine the impact of using age-
specific cut-offs for FIB-4 to triage patients [18]. The impact of using 
alternative ELF™ cut-offs for detection of advanced fibrosis was investigated 
including the manufacturer’s recommendation (ELF™=9.8) and the threshold 
recommended in recent NICE guidance on NAFLD (ELF™=10.51)[19].
In order to determine the effectiveness of the pathway compared to Standard 
Care, the outcomes of patients referred using the NAFLD pathway were 
compared to those of patients referred from C&I prior to introduction of the 
pathway; and to those of patients referred using Standard Care from C&I and 
from other CCGs during the evaluation period following introduction of the 
pathway.
In order to determine the effectiveness of the introduction of the pathway to all 
general practices across the two CCGs of C&I, outcomes for all patients 
referred from C&I, irrespective of the use of the NAFLD pathway, were 
compared to those of patients referred from all other CCGs where the 




Statistical analyses were performed using SPSS (version 22, SPSS Inc., 
Chicago, IL, USA). The odds ratios for differences in outcomes for patients 
managed in accordance with the pathway and those managed using Standard 
Care were calculated, along with 95% confidence intervals and chi-square 
tests for statistical significance using Medcalc statistical software (MedCalc 
Software 2018). 
Ethical Approval: 
The Royal Free London NHS Foundation Trust Research and Development 
Department judged this study to be an evaluation of a service improvement 
innovation, therefore this was registered for audit (EDGE ID:122031) but not 
subject to review by an independent ethics committee and individual patient 
consent was not sought. All activities were performed in accordance with the 





Between 01/03/2014 and 31/05/2016 in C&I CCGs, 3,012 patients were 
coded as having NAFLD, with an equal distribution in the numbers entered 
into the NAFLD pathway and Standard Care (Table 1). Seventy-two per cent of 
eligible practices (52/72) used the NAFLD pathway to stratify a proportion of 
their patients. Patients entered into the NAFLD pathway compared to Standard 
Care were older (54.4 years vs. 51.5, P<0.001), had a higher prevalence of 
treated type 2 diabetes (27.6% vs. 21.0%, P<0.001) and hypertension (41.7% 
vs. 33.0%, P<0.001), and less dyslipidaemia (13.5% vs. 14.6%, P<0.001). 
There were no significant differences in Q-Risk2 score, HbA1c, 
transaminases, platelet counts or HDL. The distribution of calculated FIB-4 
scores in 695 cases for which the data were available was identical between 
the patients managed using the NAFLD pathway and those managed using 
Standard Care <1.30: 513/695 (73.8%); 1.30-3.25: 162/695 (23.3%); >3.25: 
20/695 (2.9%).
Stratification of NAFLD patients in primary care using the NAFLD 
Pathway
Between 2012-13 and 2014-16 the number of patients assigned READ codes 
in the electronic patient records per annum by GPs in C&I increased from 
601/year to 1,506/year, representing a 2.5-fold increase. The number of cases 
of NAFLD referred from C&I GPs nearly doubled from 83 in 2012-13 to 329 in 
2014-16 (164.5/year). However, taking into account the increased coding, the 
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proportion of NAFLD coded patients referred to secondary care from all C&I 
GPs fell from 13.8%(83/601) to 10.9%(165/1506).
Comparison of the distribution of FIB-4 scores of patients referred for NAFLD 
by C&I GPs before and after introduction of the NAFLD pathway revealed no 
evidence of bias in patient selection (Supplementary Table 2).
Over two years, 1,452 patients were risk-stratified for the presence of 
advanced fibrosis using FIB-4 (Figure 2). FIB-4 score <1.30 was calculated in 
1,022 patients (71.3%), whilst 43 patients (3.0%) had FIB-4 >3.25.  The 
remaining 387 patients had an indeterminate FIB-4 score (1.30-3.25) and 
proceeded to an ELF test. Of these, 155  (40.0%) had ELF<9.5, and 232 
(60.0%) had ELF>9.5. In total, 1,177 patients were stratified as being at low 
risk of advanced fibrosis (81.1%) and remained in the primary care setting. 
The remaining 275 patients (18.9%) were recommended for referral to a 
specialist for further investigation. The GPs referred 152 of these 275 patients 
(55.3%) for specialist investigation within the follow up period (Figure 3). To 
interrogate the reasons for non-referral, 3 surgeries were audited 
including 32 of the non-referrals. In this sub-group, reasons for non-
referral included: patient already under the care of a hepatologist (n=4), 
inappropriate for pathway due to alcohol excess (n=2), comorbidity 
precluding need for specialist review (n=1), continued monitoring in 
primary care (n=3) awaiting outpatient appointment at time of evaluation 
(n=2), and lost to follow up (n=2). Reasons were not recorded for 18 
patients. Process evaluation revealed that 37/152 (24.3%) referrals had 
normal LFT’s, and therefore should not have been on the pathway. Of the 
patients referred to secondary care using the NAFLD pathway, hepatologists 
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judged that 29.6% had advanced fibrosis and 14.5% had cirrhosis compared 
to 4.8% and 3.6% respectively prior to introduction of the NAFLD pathway. 
Advanced fibrosis or cirrhosis was identified by liver biopsy (n=14, 
31.1%), Fibroscan (n=25, 55.6%) or radiological features of cirrhosis (n=6, 
13.3%). Of the 45 patients with advanced fibrosis or cirrhosis, 7 patients 
were referred due to FIB-4 alone (of which 6 were cirrhotic) and 38 due 
to the combination of FIB-4 and ELF.
Referrals made using the NAFLD Pathway compared to Standard Care 
during the evaluation period 
Comparison was made for referrals from C&I GPs using the pathway to GPs 
in C&I using Standard Care; and to GPs using Standard Care in other CCGs 
where the pathway had not been discussed or introduced (tables 2 and 3). 
The NAFLD pathway was 5 times better at selecting cases of advanced 
fibrosis and cirrhosis than Standard Care. When compared to Standard Care 
referrals from C&I, use of the pathway improved detection of advanced 
fibrosis and cirrhosis 4.9-fold (OR=4.90; 95%CI=2.56-9.36; p<0.0001) and 
when compared to referrals made by GPs outside C&I using Standard Care 
the pathway improved detection 5.2-fold (OR=5.18; 95%CI=2.97-9.04; 
p<0.0001). This equates to an 81% reduction in unnecessary referrals from 
primary care (OR=0.193; 95%CI=0.111-0.337; p<0.0001) when the pathway 
was used. 
Hepatologists diagnosed more cases of cirrhosis amongst patients referred 
using the NAFLD pathway compared to those referred by C&I GPs using 
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Standard Care (22/152 (14.5%) compared to 10/177 (5.6%)). This equates to 
nearly a 3-fold improvement in the detection of cases of cirrhosis (OR=2.83; 
95%CI=1.29-6.18; p=0.009). The number of referrals required to detect one 
case of advanced fibrosis was 3.4 using the pathway compared to 12.6 using 
Standard Care. 
Comparison of the NAFLD pathway with Standard Care provided by other 
CCGs during the evaluation period revealed similar results to those observed 
when comparing the pathway and Standard Care used by GPs within C&I 
(see Table 3 and Supplementary Data).
Referrals made from Camden and Islington Before and After 
Introduction of the NAFLD Pathway
Due to the increased awareness of NAFLD in 2014-16 compared to 2012-13, 
rates of referral to secondary care were analysed proportionate to the number 
of contemporaneously coded NAFLD cases, rather than comparing the 
absolute numbers of cases referred and detected per year.  
Prior to the pathway introduction in one year 79/83 (95.2%) referrals made to 
secondary care were deemed unnecessary. Following introduction of the 
NAFLD pathway over a period of 2 years, the number of unnecessary 
referrals fell to 107/152 (70.4%) representing an 88% reduction when the 
pathway was followed  (OR=0.12; 95%CI=0.042-0.349; p<0.0001) (Tables 
2,3). The improvement in selection of cases of advanced fibrosis led to an 
increase in the number of cases of cirrhosis detected from 3/83 (3.6%) to 
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22/152 (14.5%), a 74% improvement (OR=0.259; 95%CI=0.075-0.892; 
p=0.0323) representing 8 additional cases of cirrhosis per year.
There were no statistically significant differences in the outcomes for patients 
managed using Standard Care before or after introduction of the pathway 
suggesting that there was no Hawthorne or bystander effect [20] from 
diffusion of the benefits of the pathway to patients managed using Standard 
Care. 
The impact of using age-adjusted FIB-4 thresholds
Subsequent to the design and implementation of the NAFLD pathway the 
influence of age on FIB-4 was investigated, leading to a recommendation to 
adjust the threshold of FIB-4 score in people aged over 65[18]. While adopting 
this higher threshold would have reduced the number of unnecessary referrals 
to secondary care by 29 from 122 to 93, (23% reduction), this would result in 
the loss of 12 cases with advanced fibrosis of which 4 had cirrhosis (Table 2).
Modelling of the impact of other ELF™ Thresholds
The effect of using the ELF threshold proposed by NICE (10.51) [19] and the 
manufacturers of ELF (9.8) [21] rather than the threshold selected by the 
NAFLD pathway working group was investigated in the referral population 
(Table 4). Employing a threshold of 9.8 would have avoided 11 (7.2%) 
unnecessary referrals but with a concomitant loss of 3 (6.7%) cases of 
advanced fibrosis. Use of an ELF™ threshold of 10.51 would reduce the 
number of inappropriate referrals by 34 (22%), at a cost of missing 10 cases 
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In this study, we report the results of a prospective, pragmatic, real 
world pathway to triage patients with NAFLD in primary care using non-
invasive fibrosis tests based on their risk of advanced fibrosis. This 
represents the largest reported primary care cohort of patients with 
NAFLD to date. The NAFLD pathway reduced the proportion of unnecessary 
referrals of NAFLD cases while at the same time improved detection of 
advanced fibrosis and cirrhosis. When the NAFLD pathway was followed, it 
resulted in a reduction in unnecessary referrals by 81%, a 5-fold increase in 
the referral of cases of advanced fibrosis and cirrhosis and a 3-fold 
improvement in the detection of cases of cirrhosis. 
Prior to introduction of the pathway, the vast majority of referrals made to 
secondary care hepatologists could have been managed in primary care. We 
believe that this pattern of referral is common for NAFLD. Reducing 
inappropriate referrals represents an opportunity to reduce unnecessary 
investigations, inconvenience and even harm for patients, pressure on 
secondary care services and costs for the healthcare system. The NAFLD 
pathway processed 1,452 patients in 2 years demonstrating the ability to 
function at scale and manage the rising prevalence of NAFLD.
Compared to other studies in the general population, this is the first that 
specifically focused in patients with established NAFLD and also 
provided a comprehensive algorithm for referral to secondary care. 
Other studies in primary cared screened patients with risk factors for 
NAFLD or alcohol-related liver disease or general population cohorts 
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based on specific age cut-offs[22]. Moreover, most such studies have 
failed to report on the outcome of positive screening results, i.e. on the 
proportion of patients who truly had advanced fibrosis or cirrhosis. 
The NAFLD pathway working group elected to use blood tests to stratify liver 
fibrosis severity rather than transient elastography that has been used in other 
successful pathways[23]. Blood tests have the advantages that they are easily 
incorporated into routine investigations in primary care, require no specialist 
equipment, training or operation and have a lower diagnostic failure rate 
compared to elastography-based methods including FibroScan®, which has 
failure rates between 5-15% of cases, especially in NAFLD[24]. 
Application of the first stage “simple” and inexpensive test, FIB-4, allowed us 
to prevent referral of 70.3% of cases of NAFLD detected in primary care who 
did not have evidence of advanced fibrosis. However use of FIB-4 alone only 
permitted the selection of just 3.0% of cases for referral to secondary care 
with high probability of cirrhosis. Addition of the “direct biomarker” ELF™ test 
was only required in 26.7% of cases in the pathway, but the additional use of 
ELF avoided inappropriate referral for 40.1% of those with indeterminate FIB-
4 results. It is therefore important to underline that over two thirds of 
patients with NAFLD can be reassured with the use of readily available 
inexpensive tests.
Following introduction of the pathway, only 19% of cases of NAFLD 
diagnosed in primary care were deemed suitable for referral to secondary 
care. Although not appropriate to compare this proportion with referral 
practice prior to the pathway introduction, it is noteworthy that using the same 
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criteria, 93% of patients referred to secondary care prior to the pathway 
introduction were judged to have been unnecessary.
The beneficial effects of the pathway were restricted to cases that followed 
the pathway. During the evaluation period, despite evidence of improved 
awareness of NAFLD, suggested by increased coding of NAFLD, there was 
no evidence of improvement in case detection or any reduction in 
unnecessary referrals when Standard Care was followed rather than the 
pathway. This demonstrates the value of use of the pathway but also 
shows that there was no diffusion of the pathway benefits to patients 
managed with Standard Care or any significant change in “standard” 
practice due to emerging awareness of NAFLD during the evaluation 
period.
Only 48% of referrals from C&I were made using the NAFLD pathway. 
Despite this, introduction of the pathway produced significant 
improvements in referral practice even when referrals made using 
Standard Care were included in the analysis. This demonstrates the 
success of the service improvement delivered in the context of routine 
clinical care despite moderate adoption and suggests that the results 
are generalizable. More widespread use of the NAFLD pathway could result 
in even greater improvements in efficiency and the detection of cases of 
advanced fibrosis. This might be achieved with more extensive efforts to 
disseminate the pathway and insistence that the pathway should be adopted 
for all NAFLD referrals.
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Use of an age-adjusted FIB-4 threshold or of a higher ELF™ threshold 
according to the manufacturer’s or the NICE recommendation would have 
improved the positive predictive value of the NAFLD pathway for detection of 
advanced fibrosis at the expense of increased number of false negative cases. 
We believe that the use of such thresholds is not justified in this context 
as the reduction in referral numbers carries significant risks of missing 
cases that would benefit from specialist care and would be difficult to 
implement in primary care. Individual healthcare commissioners may decide 
to prioritize the detection of advanced fibrosis and long-term cost 
effectiveness over shorter term cost savings associated with avoiding referral 
of patients with lesser degrees of fibrosis.
Prior to introduction of the NAFLD pathway, funders expressed concern that 
the pathway might lead to a marked increase in referrals to secondary care 
leading to greater costs. Despite an increase in the diagnosis of NAFLD 
between 2012-2016 denoted by the increase in the coding of patients for 
NAFLD, use of the pathway resulted in a 3% reduction in the proportion of 
NAFLD cases that were referred to secondary care per year whether or not 
the pathway was followed and only a modest increase in the number of 
patients referred. 
The strengths of this study include the prospective collection of real world 
data, the size of the cohort, which is the largest primary UK cohort with 




The limitations mostly stem from the nature of the implementation design, 
which was designed to evaluate a health service innovation. It was not 
possible to conduct a randomized controlled trial because of the commitment 
to adopt the pathway once it was discussed with GPs and public health 
clinicians who formed the opinion that there was sufficient evidence to 
implement the pathway without a trial. This view was subsequently endorsed 
by NICE in the NAFLD Guidance24.
The NAFLD pathway evaluation lacked a hard outcome measure of liver 
fibrosis and rather used the composite clinical judgement of an expert clinician 
blinded to the pathway use. The secondary care evaluation of the included 
patients thus reflects real world practice, with an inevitable degree of 
selection bias in the patients undergoing liver biopsy.
Similarly the lack of formal evaluation of the prevalence of fibrosis amongst 
patients allocated to remain in primary care prevented assessment of the 
“false negative” rate for the pathway allocation. However longer term follow-up 
for clinical outcomes and more detailed health economic analyses will reveal 
the clinical impact of stratification and the true cost effectiveness of the 
pathway. Patient and service provider acceptance is being gathered and will 
be reported in due course.
Conclusions 
The Camden and Islington NAFLD pathway improved the selection of patients 
with advanced fibrosis and cirrhosis for referral to secondary care, reducing 
unnecessary referrals. This in turn delivers improvements in the detection of 
serious liver damage, better use of healthcare resources and immediate cost 
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savings. The reduction in referrals to secondary care reduces strain on 
services that are confronting a rising prevalence of obesity and NAFLD as 
well as benefitting patients’ experiences by avoiding unnecessary clinic 
appointments and investigations. This is the first study to incorporate the BSG 
guidance on the management of NAFLD and validates the recommendation to 
use FIB-4 and ELF™ for two-stage stratification. The NAFLD pathway is 
highly generalizable, as GPs will have access to both FIB-4 and ELF tests 
through most biochemistry laboratories.
It remains to be seen if the use of the NAFLD pathway delivers benefits in 
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Table 1: Patient demographics




































































































































HDL, mmol/L 1.3 ± 0.4 1.3 ± 0.4 N.S. 1.3±0.4 1.4±0.4 1.3±0.4 0.006
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Abbreviations: BMI: Body Mass Index, T2DM: type II diabetes mellitus, HDL: 




Table 2: Clinical estimates of liver fibrosis for patients diagnosed with NAFLD 
before and after introduction of the Camden and Islington NAFLD Pathway























CCGs C&I Path FIB-4 
>2.0
n= 83 109 192 152 177 329 293 470 622 93
<F3 79 100 179 107 163 270 271 434 541 60
<F3 % 95.2% 91.7% 93.2% 70.4% 92.1% 82.1% 92.5% 92.3% 87% 64.5%
F3&F4 4 9 13 45 14 59 22 36 81 33
F3&F4% 4.8% 8.3% 6.8% 29.6% 7.9% 17.9% 7.5% 7.7% 13% 35.5%
F4 3 4 7 22 10 32 15 25 47 182
F4% 3.6% 3.7% 3.6% 14.5% 5.6% 9.7% 5.1% 5.3% 7.5% 19.4%
Abbreviations: C&I: Camden and Islington. CCG: Clinical Commissioning Group
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Table 3: Impact of Implementation of The Camden and Islington NAFLD Pathway







Proportion 95%CI Significance Odds Ratio 95%CI Significance Odds Ratio 95%CI SignificanceC&IP C&I Before 88% 75-96% p=0.0001 8.30 2.87-24.05 p=0.0001 4.51 1.31-15.56 p=0.017C&IP C&I STANDARD CARE 80% 61-89% p<0.0001 4.90 2.56-9.36 p<0.0001 2.83 1.29-6.18 p=0.0092C&IP Other CCGs 81% 66-89% p<0.0001 5.18 2.97-9.04 p<0.0001 3.14 1.57-6.24 p=0.0011All of C&I Other CCG 77% 35-92% p=0.006 4.32 1.52-12.25 p=0.006 2.87 0.86-9.62 p=0.0871
Abbreviations: C&I: Camden and Islington. CCG: Clinical Commissioning Group
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Table 4: Impact of using different ELF thresholds for patient stratification
ELF≥9.8 ELF≥10.51
Relative to ELF≥9.5 n % n %
Referrals avoided 11 7.2 34 22.4
Missed Cases of F3/F4 fibrosis 3 6.7 10 22.2
Missed Cases of Cirrhosis 0 3 13.6
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Figure 1: The Camden and Islington NAFLD Pathway
Figure 2: Primary Care Risk Stratification Using the Camden and Islington NAFLD Pathway 2014-2016
Figure 3: Liver specialists’ evaluation of referrals to secondary care of NAFLD cases in the evaluation period 2014-2016











 Our study has shown that established blood tests can be used in primary care to stratify patients with fatty liver disease
  This two-step pathway (FIB-4 followed by ELF if required) reduced unnecessary referrals by 80% and improved the detection of cases 
of advanced fibrosis 5-fold and cirrhosis 3-fold.
 In the face of a growing burden of NAFLD established this pathway can be used in primary care to differentiate those patients who 
might benefit from referral to liver specialists from those who can be managed safely in primary care. 
 This should reduce unnecessary referrals while at the same time improving the detection of cirrhosis, improving patient care and 
healthcare resource use.
